Associate Professor and Director of Genitourinary Cancers
Radiation Oncology
Dr. Mark K. Buyyounouski, MD
|
|
Give Review
Mark K. Buyyounouski is an expert in the field of Radiation Oncology. He studied medicine at Rutgers New Jersey Medical School. Rutgers New Jersey Medical School has a rank of 76 in research and a 0 in primary care He received 2 awards: "Regional Top Doctor" and "CMS Meaningful Use Stage 1 Certification". Mark Buyyounouski is a published doctor. He has 71 papers published. The most current publication "SBRT and HDR brachytherapy produce lower PSA nadirs and different PSA decay patterns than conventionally fractionated IMRT in patients with low- or intermediate-risk p..." He is registered with Medicare.
Publications
- The case for Prostate brachytherapy in the Affordable Care Act era.
- Development and preliminary testing of PROGRESS: a Web-based education program for prostate Cancer survivors transitioning from active treatment.
- Salvage low-dose-rate (125)I partial Prostate brachytherapy after dose-escalated external beam radiotherapy.
- Evaluating toxicity from definitive radiation therapy for prostate Cancer in men with inflammatory bowel disease: Patient selection and dosimetric parameters with mode...
- Tadalafil for prevention of erectile dysfunction after radiotherapy for prostate Cancer: the Radiation Therapy Oncology Group [0831] randomized clinical trial.
- Randomized trial of hypofractionated external-beam radiotherapy for prostate Cancer.
- Prostate Cancer: Stratifying intermediate-risk patients for radiotherapy.
- Transurethral surgery and twice-daily radiation plus paclitaxel-cisplatin or fluorouracil-cisplatin with selective Bladder preservation and adjuvant chemotherapy for p...
- Gleason Scoring at a Comprehensive Cancer Center: What's The Difference?
- Reduction of Prostate intrafractional motion from shortening the treatment time.
- A Novel Method for Predicting Late Genitourinary Toxicity After Prostate Radiation Therapy and the Need for Age-Based Risk-Adapted Dose Constraints.
- In reply to cheung.
- A Phase 3 Trial of Whole Brain Radiation Therapy and Stereotactic Radiosurgery Alone Versus WBRT and SRS With Temozolomide or Erlotinib for Non-Small Cell Lung Cancer ...
- The impact of dose-escalated radiotherapy plus androgen deprivation for prostate Cancer using 2 linked nomograms.
- The addition of amifostine to carboplatin and paclitaxel based chemoradiation in locally advanced non-small cell lung Cancer: Long-term follow-up of Radiation Therapy ...
- Androgen deprivation therapy toxicity and management for men receiving radiation therapy.
- Aspirin and statin nonuse associated with early biochemical failure after Prostate radiation therapy.
- Assessment of the American Joint Committee on Cancer staging (sixth and seventh editions) for clinically localized prostate Cancer treated with external beam radiother...
- Effect of Gold Marker Seeds on Magnetic Resonance Spectroscopy of the Prostate.
- Hypoxic prostate/muscle po(2) ratio predicts for outcome in patients with localized prostate Cancer: long-term results.
- Young age under 60 years is not a contraindication to treatment with definitive dose escalated radiotherapy for prostate Cancer.
- Radiotherapy Doses of 80 Gy and Higher are Associated with Lower Mortality in Men with Gleason Score 8 to 10 Prostate Cancer.
- Long-term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate Cancer.
- Intensity-modulated radiotherapy reduces gastrointestinal toxicity in patients treated with androgen deprivation therapy for prostate Cancer.
- PSA Doubling Time Predicts for the Development of Distant Metastases for Patients Who Fail 3DCRT Or IMRT Using the Phoenix Definition.
- Stereotactic body radiotherapy for early-stage non-small-cell lung Cancer: report of the ASTRO Emerging Technology Committee.
- Androgen deprivation therapy in high-risk prostate Cancer.
- An intraoperative real-time sleeved seed technique for permanent Prostate brachytherapy.
- Stereotactic body radiotherapy for primary management of early-stage, low- to intermediate-risk prostate Cancer: report of the American Society for Therapeutic Radiolo...
- Development of RTOG consensus guidelines for the definition of the clinical target volume for postoperative conformal radiation therapy for prostate Cancer.
- Gains from real-time tracking of Prostate motion during external beam radiation therapy.
- Androgen deprivation therapy and prostate Cancer duration.
- Surveillance for stage I seminoma: better the devil you know than the devil you don't?
- RTOG GU Radiation oncology specialists reach consensus on pelvic lymph node volumes for high-risk prostate Cancer.
- Does treatment duration affect outcome after radiotherapy for prostate Cancer?
- Residual prostate Cancer after radiotherapy: a study of radical cystoprostatectomy specimens.
- A comparison of acute and chronic toxicity for men with low-risk prostate Cancer treated with intensity-modulated radiation therapy or (125)I permanent implant.
- Does transurethral resection of prostate (TURP) affect outcome in patients who subsequently develop prostate Cancer?
- How can men destined for biochemical failure after androgen deprivation and radiotherapy be identified earlier?
- Percentage of biopsy cores positive for malignancy and biochemical failure following prostate Cancer radiotherapy in 3,264 men: statistical significance without predic...
- Interval to biochemical failure highly prognostic for distant metastasis and prostate Cancer-specific mortality after radiotherapy.
- The Phoenix definition of biochemical failure predicts for overall survival in patients with prostate Cancer.
- Intensity Modulated Radiation Therapy Reduces Gastrointestinal Toxicity in Patients Treated with Androgen Deprivation Therapy for Prostate Cancer.
- What dose of external-beam radiation is high enough for prostate Cancer?
- Timing of biochemical failure and distant metastatic disease for low-, intermediate-, and high-risk prostate Cancer after radiotherapy.
- Role of radiotherapy in ductal (endometrioid) carcinoma of the Prostate.
- The proportion of prostate biopsy tissue with Gleason pattern 4 or 5 predicts for biochemical and clinical outcome after radiotherapy for prostate Cancer.
- Radiation dose and late failures in prostate Cancer.
- Prostate-specific antigen nadir within 12 months of prostate Cancer radiotherapy predicts metastasis and death.
- Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate Cancer on a randomized hypofractionation dose escalation trial.
- Defining biochemical failure after radiotherapy with and without androgen deprivation for prostate Cancer.
- Biochemical failure and the temporal kinetics of Prostate-specific antigen after radiation therapy with androgen deprivation.
- FDG PET imaging of signet-ring cell adenocarcinoma of the stomach.
- In regard to Selek et al. erectile dysfunction and radiation dose to penile base structures: a lack of correlation. IJROBP 2004;59:1039-1046.
- The radiation doses to erectile tissues defined with magnetic resonance imaging after intensity-modulated radiation therapy or iodine-125 brachytherapy.
- Re: improved clinical staging system combining biopsy laterality and TNM stage for men with T1c and T2 prostate Cancer: results from the search database.
- Intensity-modulated radiotherapy with MRI simulation to reduce doses received by erectile tissue during prostate Cancer treatment.
- Positive Prostate biopsy laterality and implications for staging.
- Evaluation of the Prostate Cancer Prevention Trial Risk calculator in a high-risk screening population.
- Implantation of electromagnetic transponders following radical Prostatectomy for delivery of IMRT.
- Radiotherapy: PSA nadir predicts long-term mortality.
- Predictors of androgen deprivation therapy efficacy combined with prostatic irradiation: the central role of tumor stage and radiation dose.
- Dosimetric comparison of stereotactic body radiotherapy using 4D CT and multiphase CT images for treatment planning of lung Cancer: evaluation of the impact on daily d...
- Race, genetic West African ancestry, and prostate Cancer prediction by prostate-specific antigen in prospectively screened high-risk men.
- Prostate Cancer risk assessment program: a 10-year update of Cancer detection.
- Unexpected dementia following prophylactic cranial irradiation for small cell lung Cancer: case report.
- Impact of pelvic nodal irradiation with intensity-modulated radiotherapy on treatment of prostate Cancer.
- Microvessel density in prostate Cancer: lack of correlation with tumor grade, pathologic stage, and clinical outcome.
- Prostate Cancer gene therapy and the role of radiation.
- SBRT and HDR brachytherapy produce lower PSA nadirs and different PSA decay patterns than conventionally fractionated IMRT in patients with low- or intermediate-risk p...
Schools
UmdnjNew Jersey Medical School
St Barnabas
Fox Chase Cancer Center
Lafayette College
Procedures Preformed
- Image-Guided Radiation Therapy (IGRT)
- Intensity-Modulated Radiation Therapy (IMRT)
Conditions Treated
- Bladder Cancer
- Prostate Cancer
- Testicular Cancer
- Vulvar Cancer
Doctors Specialties
- Radiation Oncology
Accepted Insurances
Awards
- Regional Top Doctor
- CMS Meaningful Use Stage 1 Certification
Education
-
Fox Chase Cancer Center -
St Barnabas Medical Center -
Rutgers New Jersey Medical School
Hospital
-
Stanford Health Care
Drug Facts
| NPI NUMBER | 1912927021 | |
| NPPES Provider LastName | BUYYOUNOUSKI | |
| NPPES Provider FirstName | MARK | |
| NPPES Provider ZIPCode | 191112434 | |
| NPPES Provider State | PA | |
| Specialty Description | Radiation Oncology | |
| Total Claim Count | 117.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1912927021 |
| Last Name Of The Provider | BUYYOUNOUSKI |
| First Name Of The Provider | MARK |
| View All |
Similar Doctors
|
Dr. Quynh-Thu Le, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Christopher R. King, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Scott G. Soltys, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Robert Lundahl, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Stanley E. Chism, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Wendy Hara, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Billy W. Loo Jr., MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Chuong Nguyen, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ming Teng, MD
This Doctor is OpenDoctor Recommended.
|